Clik here to view.
First patient dosed in Clarity’s registrational Phase III prostate cancer...
Sydney, Australia 23 December 2023 Highlights First patient safely dosed in the pivotal Phase III 64Cu-SAR-bisPSMA diagnostic trial. The aim of the CLARIFY trial is to detect regional nodal metastases...
View ArticleResignation of Non-Executive Directors
Sydney, Australia 16 January 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClik here to view.
Initial COBRA results: Clarity’s SAR-bisPSMA is safe and highly effective in...
Sydney, Australia 15 February 2024 Highlights Initial data from Clarity’s diagnostic Phase 1/2 trial, COBRA, confirms 64Cu-SAR-bisPSMA is safe and highly effective in detecting prostate cancer (PC)...
View ArticleClik here to view.
Additional COBRA results: SAR-bisPSMA detects lesions in the 2-millimetre range
Sydney, Australia 6 March 2024 Highlights Clarity recently reported that in its diagnostic Phase 1/2 trial, COBRA, 64Cu-SAR-bisPSMA was found to be safe and highly effective in detecting prostate...
View ArticleClik here to view.
Clarity’s theranostic prostate cancer trial advances to multi-dose phase
Sydney, Australia 15 March 2024 Highlights Cohort 3 of the theranostic SECuRE trial investigating 64Cu/67Cu-SAR-bisPSMA in metastatic castrate-resistant prostate cancer (mCRPC) has been completed in 6...
View ArticleClik here to view.
SECuRE update: First participant treated in the last cohort of dose escalation
Sydney, Australia 22 March 2024 Highlights First participant in cohort 4 (first multi-dose cohort) in the theranostic SECuRE trial has been treated with 67Cu-SAR-bisPSMA at 12GBq. The SECuRE trial is...
View ArticleClarity launches $121 million fully underwritten equity raising
Sydney, Australia 26 March 2024 Highlights Launch of fully underwritten equity raising of $121 million (before costs) The offer will comprise an institutional placement to raise approximately $101...
View ArticleClarity successfully completes Placement and Institutional Entitlement Offer
Sydney, Australia 28 March 2024 Highlights Clarity has successfully completed the Placement and Institutional Entitlement Offer component of its capital raising, raising $110 million in total The...
View ArticleDespatch of Retail Entitlement Offer Booklet
Sydney, Australia 4 April 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”) announced on Tuesday, 26 March 2024, a fully underwritten pro rata accelerated non-renounceable entitlement...
View ArticleClarity enters into Cu-67 SAR-bisPSMA Clinical Supply Agreement with...
Sydney, Australia 4 April 2024 Highlights New Clinical Supply Agreement with NorthStar for the production of 67Cu-SAR-bisPSMA drug product ensures seamless product supply as Clarity plans for upcoming...
View ArticleClarity successfully completes fully underwritten Retail Entitlement Offer
Sydney, Australia 24 April 2024 Highlights Clarity has successfully completed the fully underwritten Retail Entitlement Offer component of its capital raising, raising approximately $10.8 million...
View ArticleClik here to view.
Clarity Update: Complete response in first patient ever treated with 2 doses...
Sydney, Australia 30 April 2024 Highlights A complete response, based on Response Evaluation Criteria In Solid Tumours (RECIST v1.1) assessment, has been reported from the first patient with...
View ArticleClarity to present at three world leading conferences
Sydney, Australia 3 May 2024 Highlights Eight abstracts have been accepted by the American Urological Association (AUA), American Society of Clinical Oncology (ASCO) and Society of Nuclear Medicine...
View ArticleClarity strengthens Cu-64 network with new supply agreement with SpectronRx
Sydney, Australia 30 May 2024 Highlights Agreement with SpectronRx ensures seamless supply of the diagnostic copper-64 (Cu-64 or 64Cu) isotope for Clarity’s products which continue to progress through...
View ArticleClarity confirms no supply disruptions for its ongoing clinical trial programs
Sydney, Australia 7 June 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClarity Receives $10 million R&D Tax Incentive Refund
Sydney, Australia 24 June 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClarity signs supply agreement for Ac-225 with TerraPower Isotopes and...
Sydney, Australia 16 July 2024 Highlights Agreement signed with TerraPower Isotopes (TerraPower) for the supply of the therapeutic alpha-emitting isotope, actinium-225 (Ac-225 or 225Ac), for Clarity’s...
View ArticleClarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
Sydney, Australia 22 August 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleChanges to Clarity’s Board of Directors & Management Team
Sydney, Australia 26 August 2024 Clarity Pharmaceuticals (ASX: CU6) (“Clarity”, “the Company”), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that...
View ArticleClik here to view.
SECuRE trial advances: No dose limiting toxicities and strong preliminary...
Sydney, Australia 12 September 2024 Highlights Cohort 4 of the SECuRE trial is the first to assess multiple cycles of 67Cu-SAR-bisPSMA at the highest dose of 12GBq. The Safety Review Committee (SRC)...
View Article